Company / Capital Returned to Shareholders
Halozyme Capital Returned to Shareholders History
FY2017-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Capital Returned to Shareholders
$342.4M
FY2025
5-year range
$200.0M / $402.4M
FY2021-FY2025
Trend
+36.9%
vs FY2024
Sector context
#14 of 52
Health Care
What the data says
At $342M, Halozyme's capital returned to shareholders ranks #14 of 52 in the Health Care sector. Declined from $402M to $342M over the past 2 years.
Based on SEC 10-K filings.
$342M in FY2025 with a 3-year CAGR of +19.6%.
Declined from $402M to $342M over the past 2 years.
Health Care sector context is included.
Capital Returned to Shareholders over time
Growth rates
- 3-Year CAGR
- +19.6%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#14 of 52 in Health CareTop 27% of 52This company $342.4M Sector average $1.3B
▼
-74.3% below sector average
Key checks
Key Insights
- 3-year CAGR of +19.6%, indicating consistent growth.
- In FY2025, capital returned to shareholders increased 36.9% year-over-year.
- Ranks #14 out of 52 companies in the Health Care sector.
- Peak capital returned to shareholders was recorded in FY2023.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Capital Returned to ShareholdersValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $342.4M | +36.9% |
| FY2024 | $250.0M | -37.9% |
| FY2023 | $402.4M | +101.2% |
| FY2022 | $200.0M | +0.0% |
| FY2021 | $200.0M | - |
| FY2020 | $0 | - |
| FY2019 | $0 | - |
| FY2018 | $0 | - |
| FY2017 | $0 | - |
| FY2016 | - | - |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026